January 6, 2025 -Strategic financing will enable MolecuLight to further accelerate commercialization
Pittsburgh, PA January 6, 2025 – MolecuLight Inc.., a global medical device company pioneering point-of-care fluorescence imaging for measuring bacterial load in wounds, today announced it has secured a $27.5 million investment from Hayfin Capital Management LLP (“Hayfin”).
… Read MoreAugust 27, 2024 -
Pittsburgh, PA, USA – August 27th, 2024 – MolecuLight Corp., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and digital wound measurement, announced today that their flagship wound imaging device, MolecuLightDX, seamlessly integrates with the Intellicure EHR platform.
Wound Care Clinicians who
… Read MoreJune 4, 2024 -
Toronto, CANADA – June 4th, 2024 – MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, is proud to announce a groundbreaking study led by Drs. Charles Andersen and Alisha Oropallo, titled Enhancing Wound Care: The Synergistic Potential
… Read MoreMay 30, 2024 -
Toronto, CANADA – May 30th, 2024 – MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, celebrates the publication of a groundbreaking study in the prestigious Burns Journal. Titled “Bacterial Fluorescence Imaging as a Predictor
… Read MoreMay 2, 2024 -Wide-Spread Clinical Evidence using the MolecuLight Imaging Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care
Toronto, CANADA and London, UK – (May 1, 2024) – MolecuLight Corp., the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging
… Read MoreJanuary 25, 2024 -New Contract Expands VA Wound Care Center Access to MolecuLight i:X® and DX™ Point-of-Care Devices that Help Clinicians Manage Infection and Improve Outcomes
Pittsburgh, PA – January25, 2024 – MolecuLight Corp., the leader in point-of-care bacterial fluorescence imaging, announced today that the US Department of Veterans Affairs has awarded MolecuLight a
… Read MoreDecember 12, 2023 -The company’s compliance to SOC 2 Type II demonstrates the suitability of the design and operating effectiveness of its controls relevant to security
TORONTO, ON – (December 12, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announces
… Read MoreNovember 21, 2023 -MolecuLight Victorious in its Efforts to Prove Swift Medical Did Not Merit a Patent
Toronto, ON, CANADA, and Alexandria, VA, USA – (November 21, 2023) MolecuLight® Inc., the leader in real-time detection of elevated bacterial loads in wounds through point-of-care fluorescence imaging, is pleased to announce the United States Patent
… Read MoreNovember 2, 2023 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes
Toronto, CANADA and Las Vegas, NEVADA – (November 2, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.